港股異動 | 嘉裏物流(0636.HK)漲5.6% 投行看高公司股價至19港元
格隆匯10月14日丨嘉裏物流(0636.HK)股價繼續走強,盤中最高見16.16港元再創歷史新高,現報16.04港元,漲幅5.67%,最新總市值288億港元。大和研報指,全球製藥公司及政府正全力研發新型肺炎藥物或疫苗,作為最大冷鏈物流服務供應商,且在運輸藥品方面有豐富經驗,相信嘉裏有望取得香港政府有關疫苗計劃的物流訂單,令集團有額外盈利動力。上調對其2021至2022年每股盈利預測5至8%,以反映潛在藥物及疫苗運輸需求增加,將公司目標價由16港元調高至19港元,維持買入評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.